(Sharecast News) - GSK said its gynaecological cancer drug candidate had revealed positive results from early trials and would swiftly move to late-stage five clinical studies globally in the next few months.
The company on Sunday said Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE